Clinical Trial Update: The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating an antisense oligonucleotide intended to lower transthyretin (TTR) levels in wild-type transthyretin amyloidosis with cardiac involve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wild-type Transthyretin Amyloidosis

Drugs mentioned

• Antisense oligonucleotide targeting transthyretin (TTR)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Amyloidosis | Phase 2 | Status: WITHDRAWN